STRUCTURE AIDED DRUG DISCOVERY RESEARCH OF ANTI-MICROBIAL TARGETS

抗微生物靶点的结构辅助药物发现研究

• 批准号: 7370338
• 负责人: GYORGY SNELL
• 金额: $ 0.19万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7370338
• 关键词: STRUCTURE; AIDED; DRUG; DISCOVERY; RESEARCH

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Syrrx is a structural proteomics company based in San Diego doing structure-based drug design. Several proprietary targets of microbial proteins have been crystallized at Syrrx, characterized with monochromatic X-rays. In order to phase these we have grown and crystallized these proteins with Se-Met substitution and are seeking MAD beam time.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。Syrx是一家总部位于圣地亚哥的结构蛋白质组公司，从事基于结构的药物设计。几种微生物蛋白质的专有目标已经在Syrrx结晶，用单色X射线进行了表征。为了使这些蛋白质相态，我们已经用Se-Met替代生长和结晶了这些蛋白质，并正在寻找疯狂的束流时间。